All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Polymyositis-related chronic graft-versus-host disease
In September 2018, findings from reported cases in graft-versus-host-disease (GvHD) associated polymyositis (PM) were published in Clinical Case reports. The authors aimed to review data from two reports of polymyositis-related GvHD in order to better understand this rare complication of allogeneic hematopoietic stem cell transplantations (allo-HSCT).
Case 1
- 48-year-old woman with acute myeloid leukemia (AML), diagnosis in 2013
- Complete remission (CR) after two courses of chemotherapy
- The patient underwent allo-HSCT in February 2014 after reduced intensity conditioning
- New symptoms after 10 months: limb weakness and mild dyspnea after walking without myalgia, skin rash, or obvious dysphagia
Case 2
- 31-year-old woman with AML, diagnosis 20 months ago
- CR was achieved with two courses of chemotherapy
- Allo-HSCT after fifteen months after reduced intensity conditioning
- Hospitalization because of limb weakness and myalgia for 5 months
Test results for Patients 1 and 2 (data is given as Patient 1 and 2)
- CK (U/L): 2118 vs 18
- Lactate dehydrogenase (U/L): 528 vs 241
- Aspartate aminotransferase (U/L): 89 vs 192
- Alanine aminotransferase (U/L): 85 vs 137
- Myoglobin (ng/mL): 1057.90 vs3
- CRP (mg/L): 0.2 vs6
- Antinuclear antibodies: 1:100 vs 1:320
- Myositis autoantibody: negative in both patients
- Thyroid glands: negative in both patients
Therapy
- Patient 1
- increased dosage of prednisone and cyclosporin A (CsA), but no significant result was seen
- rituximab (100 mg) plus a low dose of intravenous immunoglobulin (IVIG, 5-10 g) weekly was applied for consecutive 6 weeks
- the patient’s CK level became normal
- Patient 2
- oral prednisone and CsA did not improve the patient’s status
- tacrolimus (3 mg QD) combined with oral methylprednisolone (40 mg QD) was implemented
- Patient 2 had been followed up for over 1 year and she is in a good condition receiving tacrolimus at 3 mg with methylprednisolone at 12 mg daily
In summary, these case reports show that patients who underwent allo-HSCT can develop T cell-mediated immunologic muscle disorder which is similar to polymyositis with comparable clinical manifestations. Corticosteroids and immunosuppressants are feasible therapy options.
References